vs
Aardvark Therapeutics, Inc.（AARD）与阿斯利康（AZN）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
AARD vs AZN — 直观对比
营收规模更大
AZN
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q2 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $14.5B |
| 净利润 | $-17.6M | $2.4B |
| 毛利率 | — | 82.9% |
| 营业利润率 | — | 24.3% |
| 净利率 | — | 16.9% |
| 营收同比 | — | 11.7% |
| 净利润同比 | — | 27.0% |
| 每股收益（稀释后） | $-0.81 | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDAZN
| Q4 25 | $0 | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | $14.5B | ||
| Q1 25 | $0 | — | ||
| Q2 24 | — | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q2 22 | — | $10.8B |
净利润AARDAZN
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | — | ||
| Q2 25 | $-14.4M | $2.4B | ||
| Q1 25 | $-9.3M | — | ||
| Q2 24 | — | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q2 22 | — | $360.0M |
毛利率AARDAZN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 82.9% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q2 22 | — | 72.2% |
营业利润率AARDAZN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 24.3% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q2 22 | — | 5.0% |
净利率AARDAZN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 16.9% | ||
| Q1 25 | — | — | ||
| Q2 24 | — | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q2 22 | — | 3.3% |
每股收益（稀释后）AARDAZN
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | — | ||
| Q2 25 | $-0.66 | $1.57 | ||
| Q1 25 | $-0.71 | — | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q2 22 | — | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | $7.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $106.6M | $44.8B |
| 总资产 | $117.2M | $112.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AARDAZN
| Q4 25 | $110.0M | — | ||
| Q3 25 | $126.3M | — | ||
| Q2 25 | $141.8M | $7.1B | ||
| Q1 25 | $151.3M | — | ||
| Q2 24 | — | $6.9B | ||
| Q2 23 | — | $5.7B | ||
| Q2 22 | — | $4.8B |
股东权益AARDAZN
| Q4 25 | $106.6M | — | ||
| Q3 25 | $122.4M | — | ||
| Q2 25 | $136.9M | $44.8B | ||
| Q1 25 | $150.7M | — | ||
| Q2 24 | — | $39.6B | ||
| Q2 23 | — | $37.4B | ||
| Q2 22 | — | $36.0B |
总资产AARDAZN
| Q4 25 | $117.2M | — | ||
| Q3 25 | $133.2M | — | ||
| Q2 25 | $147.5M | $112.4B | ||
| Q1 25 | $157.0M | — | ||
| Q2 24 | — | $104.3B | ||
| Q2 23 | — | $96.5B | ||
| Q2 22 | — | $96.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AARDAZN
| Q4 25 | $-16.8M | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.8M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流AARDAZN
| Q4 25 | — | — | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
